Federal Experts' Advice on HPV Vaccine Could Add Confusion Federal Experts' Advice on HPV Vaccine Could Add Confusion

A federal advisory panel says people aged 27 to 45 may benefit from the human papillomavirus vaccine, but some worry that the advice doesn't provide clear guidance about who are candidates for the vaccine.Kaiser Health News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news

Related Links:

Conclusions Public health educational programs that are focused and tailored on parents consenting to HPV vaccination for boys at a young age can be useful in improving HPV vaccination rates among boys. There is also a pressing need to educate boys about the benefits of HPV vaccination in males and about HPV disease susceptibility to facilitate adoption of the HPV vaccine by young adults in the future.
Source: Sexually Transmitted Diseases - Category: Sexual Medicine Tags: Original Studies Source Type: research
The objective of this quality improvement project was to increase human papillomavirus (HPV) vaccine initiation rates among males aged 11 to 21 years old. A multipronged strategy was implemented at a pediatric practice, including an electronic medical record prompt, educational presentation, and monthly e-mail updates to providers. Deidentified HPV vaccine initiation rate data were collected, and a paired 2-sample t test evaluated differences in prepost vaccine initiation rates. HPV vaccine initiation rates increased by 6.5% during the project period.
Source: The Journal for Nurse Practitioners - Category: Nursing Authors: Tags: Brief Report Source Type: research
Publication date: December 2019Source: Current Opinion in Virology, Volume 39Author(s): Silvia de Sanjose, Maria Brotons, D Scott LaMontagne, Laia BruniSince 2006, 115 countries and territories have introduced human papillomavirus (HPV) vaccination programs.Several efforts have been undertaken to evaluate the impact of HPV vaccines. Many countries, mainly high-income and with high screening coverage, are already reporting a visible impact of the HPV vaccine on HPV-related diseases. Others, largely low-income and middle-income countries, are introducing HPV vaccine to control HPV diseases that will undoubtedly generate a si...
Source: Current Opinion in Virology - Category: Virology Source Type: research
ConclusionOverall, these data support the concomitant administration of HPV4, Tdap and MenACWY-CRM in adolescents.FundingNovartis Vaccines and Diagnostics Inc., now part of the GSK group of companies.Trial RegistrationClinicalTrials.gov identifier, NCT01424644.
Source: Infectious Diseases and Therapy - Category: Infectious Diseases Source Type: research
Despite the availability of different therapeutic modalities, treatment of recalcitrant common warts is still challenging. Cervarix, a recombinant bivalent human papillomavirus (HPV) vaccine, has shown promising efficacy in the treatment of warts.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Source Type: research
CONCLUSION: Due to the low levels of knowledge about HPVinfection and its methods of prevention, efforts should be increased to enhance the knowledge of the general populationabout HPV infection and vaccination in order to prevent its incidence and complications. PMID: 31350949 [PubMed - in process]
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research
.
Source: Human Vaccines and Immunotherapeutics - Category: Allergy & Immunology Authors: Source Type: research
From September 2019, boys aged 12 and 13 years will be offered the free human papillomavirus vaccine, Public Health England  has announced.
Source: The Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
Abstract OBJECTIVE: To estimate whether targeted educational interventions can increase human papillomavirus (HPV) vaccine acceptability and knowledge among young women. METHODS: An exploratory phase of the study was conducted to determine baseline acceptance of the prophylactic HPV vaccine and barriers to acceptance. Based on the results of that phase of the study, a randomized controlled trial of women aged 12-26 at a single institution was completed. A sample size of at least 84 women in each of three study arms (control, educational handout, or educational video) was planned to detect a 20% difference in ...
Source: Obstetrics and Gynecology - Category: OBGYN Authors: Tags: Obstet Gynecol Source Type: research
AbstractEfforts to understand low human papillomavirus vaccine coverage led us to explore quality improvement (QI) decision-making programs and processes to increase vaccine uptake. These QI programs often include interventions recommended by the AFIX (Assessment Feedback Incentives eXchange) Program that supports Vaccines for Children (VFC) clinics. However, little is known about decision-making around intervention selection or extent of implementation. In collaboration with the state public health department in the rural Midwestern, investigators developed a survey to explore vaccine-related QI in VFC clinics. The survey...
Source: Journal of Community Health - Category: International Medicine & Public Health Source Type: research
More News: Cervical Cancer Vaccine | Gardasil | Genital Warts | Health | Human Papillomavirus (HPV) | Primary Care | Vaccines